15 results about "Maximum dose" patented technology

The invention discloses an anesthesia depth accurate prediction system and method based on time sequence alignment. The method comprises the steps that a cross-modal joint time sequence characteristic data matrix is acquired and generated; outputting a time sequence alignment feature sample; outputting a future advanced prediction label set; obtaining a first-stage anesthesia depth prediction model; in the first anesthesia depth prediction model training stage, a logic auditing link is introduced, and a self-adaptive online updating model is formed; starting an anti-fact dose simulation module, and outputting a candidate anti-fact administration scheme set; and inputting the candidate anti-factual administration scheme set into a dynamic security constraint optimizer, rejecting non-compliant schemes by the dynamic security constraint optimizer according to single maximum dose limitation, single additional dose and administration times in a minimum administration interval, and outputting an optimal administration suggestion. According to the method, combined classification judgment is carried out on the anesthesia state grade and the change trend of each prediction step, and the sensitivity of clinical risk identification and abnormal situation early warning is effectively improved.

The invention discloses a dose rate measurement method, device and equipment based on Poisson maximum likelihood estimation, and a storage medium, and the method comprises the steps: obtaining and preprocessing environment nuclear radiation monitoring data, and obtaining a fusion data sequence; dividing the fused data sequence into a plurality of time windows and determining an envelope spectrum sequence; performing radiation dose rate estimation on the envelope spectrum sequence through a Poisson maximum likelihood estimation method to obtain a preliminary dose rate estimation value; determining an environment correction factor according to the temperature data sequence, the humidity data sequence and the air pressure data sequence; correcting the initial dose rate estimation value to obtain a corrected dose rate estimation value; and inputting the corrected dose rate estimated value and the average dose rate and the maximum dose rate in each time window into a support vector machine model for prediction to obtain a future nuclear radiation dose rate prediction result, and updating the optimal estimated value of the dose rate in real time by introducing a Poisson maximum likelihood estimation algorithm. The accuracy and response speed of dose rate estimation are improved.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition, a method for reducing the serum uric acid level of a gout patient and application of topiromilast to preparation of a medicine for treating hyperuricemia / gout with hyperuricemia. The medicine is continuously administered according to the following dosage scheme: the initial dosage is 40-80mg / day, and the duration period is 2-4 weeks; the first adjusting dosage is 120-160mg / day, and the duration period is 2-4 weeks; the maximum dose is 160-320 mg / day, and the dose lasts for at least 8 weeks. According to the pharmaceutical composition, high-efficiency treatment of Chinese patients with hyperuricemia / gout is realized through a staged dosage increasing scheme, and renal function impairment is improved. The invention further provides a method for reducing the serum uric acid level of gout patients, continuous administration is carried out according to the dosage scheme, and the topiromilast is applied to preparation of the medicine for treating hyperuricemia / gout with hyperuricemia and is suitable for people with renal insufficiency.

The invention provides an application of a compound CTU-B2R in preparation of a medicine for treating toxoplasmosis. The compound CTU-B2R comprises CTU-B2N (the molecular formula is C28H18O3BrN3S) and / or CTU-B2Br (the molecular formula is C28H18OBr2N2S). The inventor finds and verifies that CTU-B2R has a remarkable inhibitory activity effect on intracellular parasitic protozoa toxoplasma gondii through a large number of researches, Vero cells infected with the toxoplasma gondii are used as cells of an experimental model, and EC50 determination shows that the CTU-B2N has a half of inhibitory effect on the toxoplasma gondii when the CTU-B2N is 0.7 mu M and CTU-B2Br is 0.4 mu M, and the CTU-B2R has a remarkable inhibitory activity effect on the toxoplasma gondii when the CTU-B2N is 0.7 mu M and the CTU-B2Br is 0.4 mu M. And an efficient toxoplasma gondii infection resisting effect can be achieved by applying a small amount. Meanwhile, the cytotoxicity of the CTU-B2R to the Vero is detected by a CCK8 method, and the result shows that when the dosage of the CTU-B2N and the CTU-B2Br is maximally 500 mu M, the CTU-B2N and the CTU-B2Br still have no cytotoxicity to the Vero cells. Compared with the existing drugs for treating toxoplasma gondii infection, which have the problems of large side effect, poor effect and the like, the effective inhibition concentration of the CTU-B2R provided by the invention is far less than the cytotoxicity of the CTU-B2R, and the CTU-B2R has the remarkable advantages of high efficiency, low toxicity and safety when being used for preparing the drugs for preventing or treating toxoplasma gondii infection.

A method for sterilizing by X-rays an assembly containing a single-use device intended to receive a biopharmaceutical fluid, comprising: placing a plurality of dosimeters, repeatedly passing the assembly in front of the X-ray radiation window, according to a first face then according to a second face of the assembly, at several irradiation power-time pairs (PTi), followed by mapping the radiation dose; and —determining an optimum power-time pair (PTopt) for which the mapping reveals that all dosimeters have recorded a radiation dose above a minimum sterility dose (Dmin), and for which the dosimeter associated with a fragile element of the single-use device records a radiation dose below a maximum dose (Dmax) defined as being the dose from which the X-ray irradiation deteriorates the fragile element.

The invention provides a compound MSB-2O, a preparation method and application thereof and a medicine for preventing or treating toxoplasma infection, and relates to the technical field of biological medicine, the molecular formula of the compound MSB-2O is C17H16N4O4, the compound MSB-2O has a remarkable effect of preventing or treating toxoplasma infection, the MSB-2O has a half of inhibition effect on toxoplasma when the MSB-2O is 0.6 mu M, the toxoplasma can be completely killed when the MSB-2O is 5 mu M, and the compound MSB-2O can be used for preventing or treating toxoplasma infection. An efficient toxoplasma infection resisting effect can be achieved by applying a small amount of the compound MSB-2O, the compound MSB-2O still has no cytotoxicity to green monkey kidney cells (Vero) when the maximum dosage is 500 mu M, the effective inhibition concentration of the compound MSB-2O is far smaller than that of the cytotoxicity of the compound MSB-2O, and the compound MSB-2O has the advantages of being efficient, low in toxicity and safe.

The present application relates to a kind of irradiation experimental line mechanism, including walking part and fixed part, walking part includes experimental box, the suspension chain of experimental box top and anchor iron being arranged at the bottom of experimental box are constituted;Fixed part includes the track for the walking of suspension chain, and the limiting anchor rail that is arranged below track and cooperates with anchor iron.Implementation, the experimental box can utilize irradiation device monitoring line to carry out irradiation experiment, provide effective data for small-dose gamma irradiation processing, realize the stable balance of irradiation dose range;For the effective data obtained by experimental box, draw out isodose distribution curve diagram, the index such as the statistics equivalent maximum dose area, equivalent minimum dose area, dose non-uniformity, main control time and absorbed dose relationship, so that production line can carry out small-dose precision irradiation, avoid capacity waste.

The utility model discloses a pen type syringe capable of accurately displaying residual dose, which comprises a shell, a dose adjusting part arranged on the shell, an upper rotating part arranged in the dose adjusting part, and a small dose part arranged between the dose adjusting part and the upper rotating part, when the dose is set, the small dose part moves upwards along the axial direction of the dose adjusting part, and when injection is carried out, the small dose part moves upwards along the axial direction of the dose adjusting part. The small dosage piece and the dosage adjusting piece are kept still, and when the dosage is set, the moving distance of the small dosage piece is matched with the set dosage. According to the pen type injector capable of accurately displaying the residual dose, the small dose piece is arranged between the dose adjusting piece and the upper rotating piece, when the accumulative set dose reaches the maximum dose of the injection pen, the small dose piece prevents the dose adjusting piece from intermittently setting the dose, the situation that the set dose exceeds the maximum dose, and consequently the injection dose is insufficient is avoided, and the injection quality is improved. The medication safety is improved.

Disclosed in the present invention is a dose-limiting assembly for injection, comprising a dose knob, wherein the dose knob is rotatably arranged on a force storage spring assembly; a fixed gear is fixedly arranged on an upper portion of the force storage spring assembly; a limiting gear is rotatably arranged inside the dose knob; and the limiting gear meshes with the fixed gear. During dose setting, the dose knob is rotated to drive the limiting gear to rotate; and during injection, the positions of the limiting gear, the fixed gear and the dose knob remain unchanged, and when a cumulatively set dose of the dose knob reaches the predetermined maximum dose, the limiting gear restricts the dose knob from rotating. In the dose-limiting assembly for injection of the present invention, the limiting gear is arranged between the force storage spring assembly and the dose knob, and when the dose knob is rotated by a maximum dose-setting number of turns, the limiting gear restricts the dose knob from rotating, so as to prevent a set dose for the last injection from exceeding a remaining dose of a medicinal liquid, thereby preventing harm to the health of a patient caused by the inaccurate amount of an injected drug.

The invention relates to the technical field of drug testing, in particular to a clinical test scheme design and multi-dimensional data construction analysis method. The method comprises the following steps: S1, designing a clinical test scheme, wherein a dosage scheme comprises an initial dosage, a maximum dosage, a titration period and a treatment maintaining period; s2, constructing a multi-dimensional data set: constructing the multi-dimensional data set based on the collected object, wherein the multi-dimensional data set comprises a total analysis set FAS, a security analysis set SS and a coincidence scheme set PPS; and S3, carrying out statistical analysis on the multi-dimensional data, wherein the statistical analysis comprises validity analysis and security analysis. By reasonably setting a plurality of visiting points such as dosage of a test group and a control group, a titration period, a treatment maintaining period, a screening period, a baseline period, a treatment period, a follow-up visit period and the like, a multi-dimensional data set containing abundant visiting point acquisition data is constructed; and the curative effect of the topiromilast tablet in patients with gout with hyperuricemia in China is accurately evaluated.

This invention proposes a limiting device for setting the maximum single-dose dosage of an injection pen, comprising a housing, with a proximal end at the front end and a distal end at the rear end. A dose display element is spirally connected to the housing. During injection, the dose display element moves towards the distal end along the thread of the housing. During dose adjustment, the dose display element moves towards the proximal end along the thread of the housing. A limiting protrusion is provided on the inner wall of the housing, and a notch is provided on the upper surface of the dose display element. The notch is inclined. When adjusted to the maximum dose, the side of the notch abuts against the side of the limiting protrusion, limiting the continued rotation of the dose display element, thereby limiting the maximum single-dose dosage and preventing the set dose from exceeding the maximum single-dose dosage, resulting in inaccurate single-injection administration.

The invention provides a micro-focus ray source dose calculation method and device and related equipment, and belongs to the technical field of micro-focus ray sources. A micro-focus ray source dose calculation method comprises the following steps that at least one gear is determined, original data of the corresponding gear are obtained, and the original data comprise dose data at least larger than the number of sampling samples; processing the original data based on a preset rule to obtain a plurality of first fitting data and a plurality of second fitting data; respectively calculating an average dose value, a dose fluctuation rate and a dose change rate according to the first fitting data and the second fitting data; and judging whether the average dose value, the dose fluctuation rate and the dose change rate are qualified or not according to a preset standard threshold value, and outputting a result. The method has the advantages that judgment bases such as the dose fluctuation rate and the dose maximum change rate are accurately calculated, and meanwhile the labor input cost is reduced.

The present disclosure provides methods of treating Friedreich's Ataxia (FRDA) in a subject that comprise administering to the subject a TAT-FXN fusion protein once daily at a dose of about 25 mg or a dose of about 50 mg. The present disclosure also provides methods of treating Friedreich's Ataxia (FRDA) in a pediatric subject that comprise administering to the subject a TAT-FXN fusion protein once daily at a dose of about 0.8 mg / kg, up to a maximum dose of about 50 mg. The present disclosure also provides methods of increasing the level of frataxin (FXN) in an FXN-decifient subject, e.g., pediatric subject.

To provide a method for treating insomnia that is effective and safe even when lemborexant is administered to a patient having moderate hepatic impairment.SOLUTION: Provided is a method comprising orally administering to a patient in need thereof a dosage form comprising lemborexant or a pharmaceutically acceptable salt thereof at a single daily dose ranging from 5 mg to 10 mg of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof, provided that when the patient has moderate hepatic impairment classified as Child-Pugh class B under Child-Pugh Classification, the maximum dose is 5 mg once per day of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof.SELECTED DRAWING: Figure 1

A composition and drug-device combination product for local tumor injection, and the use thereof in the preparation of a drug for local tumor injection administration. The composition comprises an anti-tumor pharmaceutical ingredient, an immune adjuvant and a pharmaceutical carrier. By means of a specially designed jet microneedle delivery device, an anti-tumor drug can be locally administered to a tumor, thus avoiding the problem that traditional intravenous administration limits the maximum dose and therapeutic effect of the drug due to systemic toxicity. High-concentration local administration of the composition not only improves the local therapeutic effect on the tumor, but also can effectively produce a tumor antigen. In the subsequent course of treatment after the initial treatment, only a composition of an immune adjuvant and a tumor-specific polypeptide, or the immune adjuvant alone, can be administered to maintain and enhance the established tumor-specific immune response, avoiding the cumulative toxicity caused by repeated use of chemotherapeutic drugs.